Longeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC) Data from Longeveron's CLEAR MIND Phase 2a clinical trial evaluating Lomecel-B in Alzheimer’s Disease has been accepted for two presentations at AAIC.

Longeveron Announces Closing of $5.2 Million Public Offering Longeveron announces closing of previously announced public offering, raising $5.25 million in gross proceeds.

Longeveron Announces Pricing of $5.25 Million Public Offering Longeveron prices $5.15 million public offering with certain board member and insider participation.

Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals CEO Letter to Shareholders. Update on overall strategy, business objectives, approach to capital allocation, and 2024 key priorities and goals.

LGVN SHAREHOLDER ALERT: ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Longeveron Inc. Investors to Secure Counsel Before Important November 12 Deadline in Securities Class Action – LGVN NEW YORK, Nov. 01, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Longeveron Inc. (NASDAQ: LGVN): (1) pursuant and/or...